| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99281 |
Emergency department visit for the evaluation and management, self-limited or minor |
5,915 |
5,276 |
$195K |
| 0450 |
Emergency room services |
6,180 |
5,529 |
$149K |
| 70450 |
Computed tomography, head or brain; without contrast material |
1,625 |
1,569 |
$127K |
| 74176 |
Computed tomography, abdomen and pelvis; without contrast material |
1,250 |
1,207 |
$119K |
| 99284 |
Emergency department visit for the evaluation and management, high severity |
1,434 |
1,366 |
$111K |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
2,652 |
2,478 |
$109K |
| G0481 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed |
987 |
941 |
$71K |
| J0131 |
Injection, acetaminophen, not otherwise specified,10 mg |
488 |
474 |
$66K |
| 96375 |
Therapeutic injection; each additional sequential IV push |
2,049 |
1,906 |
$50K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
3,322 |
3,099 |
$48K |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
900 |
874 |
$43K |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
202 |
199 |
$31K |
| 71045 |
Radiologic examination, chest; single view |
4,314 |
4,105 |
$30K |
| 80053 |
Comprehensive metabolic panel |
6,012 |
5,554 |
$30K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
1,388 |
1,315 |
$28K |
| 87811 |
Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) |
1,840 |
1,794 |
$28K |
| C9803 |
Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
1,628 |
1,565 |
$25K |
| 96361 |
Intravenous infusion, hydration; each additional hour |
1,573 |
1,472 |
$24K |
| 0710 |
|
288 |
279 |
$24K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
6,447 |
5,894 |
$23K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
488 |
468 |
$23K |
| 0270 |
|
3,818 |
2,879 |
$20K |
| 99199 |
Unlisted special service, procedure or report |
2,502 |
2,236 |
$18K |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
357 |
331 |
$16K |
| 84484 |
|
2,985 |
2,808 |
$14K |
| 83880 |
|
821 |
799 |
$14K |
| J7030 |
Infusion, normal saline solution , 1000 cc |
2,086 |
1,917 |
$12K |
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
122 |
102 |
$11K |
| 83690 |
|
2,510 |
2,333 |
$8K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
794 |
773 |
$8K |
| 85730 |
|
2,604 |
2,475 |
$8K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
1,856 |
1,793 |
$7K |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
1,246 |
1,202 |
$6K |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
1,768 |
1,643 |
$6K |
| 87040 |
|
747 |
693 |
$6K |
| 96360 |
Intravenous infusion, hydration; initial, 31 minutes to 1 hour |
144 |
141 |
$6K |
| 81000 |
|
3,537 |
3,327 |
$6K |
| 85610 |
|
2,665 |
2,519 |
$5K |
| 0360 |
|
188 |
176 |
$5K |
| J3490 |
Unclassified drugs |
4,927 |
3,824 |
$5K |
| 83605 |
|
899 |
850 |
$4K |
| 81025 |
|
1,862 |
1,783 |
$3K |
| J2270 |
Injection, morphine sulfate, up to 10 mg |
611 |
550 |
$3K |
| 76700 |
Ultrasound, abdominal, real time with image documentation; complete |
80 |
77 |
$3K |
| 83735 |
|
643 |
628 |
$2K |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
200 |
197 |
$2K |
| 82150 |
|
568 |
523 |
$2K |
| 43239 |
Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple |
24 |
24 |
$2K |
| 87428 |
|
202 |
201 |
$2K |
| 81002 |
|
1,140 |
1,091 |
$2K |
| 84703 |
|
378 |
361 |
$1K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
104 |
88 |
$1K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
51 |
47 |
$1K |
| 88305 |
Level IV - Surgical pathology, gross and microscopic examination |
68 |
66 |
$901.81 |
| 80048 |
Basic metabolic panel (calcium, ionized) |
233 |
221 |
$827.94 |
| J7040 |
Infusion, normal saline solution, sterile (500 ml = 1 unit) |
198 |
186 |
$766.48 |
| 82550 |
|
211 |
201 |
$686.69 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
85 |
64 |
$501.51 |
| G2023 |
Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
28 |
26 |
$492.66 |
| 71046 |
Radiologic examination, chest; 2 views |
36 |
36 |
$417.22 |
| 81015 |
|
273 |
264 |
$388.00 |
| 80076 |
|
116 |
112 |
$387.60 |
| J2765 |
Injection, metoclopramide hcl, up to 10 mg |
168 |
163 |
$320.33 |
| 73562 |
|
26 |
25 |
$301.68 |
| J2250 |
Injection, midazolam hydrochloride, per 1 mg |
285 |
273 |
$267.15 |
| 94762 |
|
13 |
13 |
$254.40 |
| 0272 |
|
606 |
543 |
$209.59 |
| 87186 |
|
44 |
43 |
$206.04 |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
208 |
200 |
$200.00 |
| 85379 |
|
43 |
42 |
$179.47 |
| 87077 |
|
44 |
43 |
$169.80 |
| 82948 |
|
134 |
125 |
$164.89 |
| 73630 |
|
13 |
13 |
$156.96 |
| 93971 |
|
12 |
12 |
$137.83 |
| J3010 |
Injection, fentanyl citrate, 0.1 mg |
198 |
192 |
$101.66 |
| J1200 |
Injection, diphenhydramine hcl, up to 50 mg |
34 |
30 |
$97.28 |
| 87280 |
|
12 |
12 |
$84.84 |
| J0690 |
Injection, cefazolin sodium, 500 mg |
42 |
39 |
$73.56 |
| 86901 |
|
53 |
51 |
$72.89 |
| 36415 |
Collection of venous blood by venipuncture |
219 |
185 |
$29.85 |
| 86900 |
|
12 |
12 |
$20.92 |
| J7120 |
Ringers lactate infusion, up to 1000 cc |
83 |
80 |
$20.75 |
| J2704 |
Injection, propofol, 10 mg |
53 |
51 |
$9.20 |
| 0637 |
|
88 |
71 |
$0.00 |